Seeking Alpha

Merck buys Idenix

  • In an all-cash deal, Merck (MRK) acquires Hep C drug maker Idenix Pharmaceuticals (IDIX) for $24.50/share ($3.85B). The company has an attractive portfolio of Hep C product candidates based on nucleotide/nucleoside chemistry and prodrug technologies.
From other sites
Comments (19)
  • Patent News
    , contributor
    Comments (1321) | Send Message
     
    wow. baupost making a huge payday
    9 Jun, 08:05 AM Reply Like
  • Patent News
    , contributor
    Comments (1321) | Send Message
     
    that means seth klarman makes about a billion$ minus cost of their shares at about 2.5 or 3
    9 Jun, 08:06 AM Reply Like
  • SWIMMER
    , contributor
    Comments (10) | Send Message
     
    Sounds like a lot of money for someone coming late to the game. Differentiation may become interesting
    9 Jun, 08:08 AM Reply Like
  • the_value_vulture
    , contributor
    Comments (205) | Send Message
     
    ...and I sold 30% of my position on Friday to shore up a higher cash position.
    9 Jun, 08:13 AM Reply Like
  • Patent News
    , contributor
    Comments (1321) | Send Message
     
    wow bad timing
    9 Jun, 08:16 AM Reply Like
  • Unconventional Capital Wisdom
    , contributor
    Comments (232) | Send Message
     
    Another example of patience beening rewarded
    9 Jun, 09:02 AM Reply Like
  • Implied Value
    , contributor
    Comments (104) | Send Message
     
    Great call(s) on IDIX. Never bet against Klarman.
    9 Jun, 10:36 AM Reply Like
  • Unconventional Capital Wisdom
    , contributor
    Comments (232) | Send Message
     
    Thanks IV
    9 Jun, 06:06 PM Reply Like
  • bhtaylor29
    , contributor
    Comments (88) | Send Message
     
    So who is next up? Im putting down money that its HALO or JAZZ. HALO for the patent cliff mix of current drugs it enhances, and JAZZ offers excellent tax advantages for any company buying it due to its HQ being in Ireland.
    9 Jun, 09:38 AM Reply Like
  • CMPMD
    , contributor
    Comments (117) | Send Message
     
    Gilead feeling some pressure due to this.
    9 Jun, 09:40 AM Reply Like
  • Menicholas
    , contributor
    Comments (520) | Send Message
     
    Anyone know when the deal will be finalized? Trying to decide whether to take the money and run now or wait for the buyout to go through.
    9 Jun, 09:45 AM Reply Like
  • dheuring
    , contributor
    Comments (8) | Send Message
     
    Don't be greedy. Take the money.
    9 Jun, 10:09 AM Reply Like
  • Welt
    , contributor
    Comments (181) | Send Message
     
    TAKE THE MONEY
    9 Jun, 12:20 PM Reply Like
  • newnnly
    , contributor
    Comments (246) | Send Message
     
    agree. take the money
    9 Jun, 05:56 PM Reply Like
  • Menicholas
    , contributor
    Comments (520) | Send Message
     
    I almost sold some on Friday.
    9 Jun, 09:45 AM Reply Like
  • Kishavan
    , contributor
    Comments (58) | Send Message
     
    Thank you Seth Klarman.
    9 Jun, 10:19 AM Reply Like
  • T-time
    , contributor
    Comments (311) | Send Message
     
    The winner here is the opportunity to buy GILD under 80 - probably LAST chance!
    9 Jun, 10:44 AM Reply Like
  • Jimghad
    , contributor
    Comments (123) | Send Message
     
    Merck Gilead and Abbvie are in the race.
    Wonder what Janssen is up to.
    They are a big Co. They are not going to roll over and play dead.
    9 Jun, 03:42 PM Reply Like
  • hessmessinc
    , contributor
    Comments (16) | Send Message
     
    Opportunity continues to buy $ONCS...
    10 Jun, 12:38 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector